19.90
0.00%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Boiron
Its shares trade on Euronext Paris under the ticker BOI.PA. It has been listed since 25 March 1991. In the fiscal year to 31 December 2025, it reported revenue of €501.1m and net income of €32.6m. At that date it held total assets of €602.8m and shareholders' equity of €392.8m.
Boiron SA engages in the manufacturing and selling homeopathic medicines. The company is headquartered in Rontalon, Auvergne-Rhone-Alpes. The firm develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. The company also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Mar 1991
- Employees
- 3,502
- Website
- boiron.fr ↗
Leadership
Pay as last reported
- Mrs. Anabelle Flory-BoironNon-Executive Chairman of the Board€15,011
- Mr. Thierry BoironChief Executive Officer, since 1996€270,443
- Mr. Jean-Christophe Michel BayssatDeputy Chief Executive Officer, Chief Pharmacist, Pharmaceutical Development Director€30,000
- Mr. Olivier BohuonNon-Executive Director - Permanent Representative of Domino Fund 3 Holdco GP LLC
- Mr. Benjamin BoironNon-Executive Director
- Ms. Laurence BoironNon-Executive Director - Permanent Representative of Boiron Development€13,025
- Mrs. Christine Boyer-BoironNon-Executive Director€13,025
- Mrs. Stephanie ChesnotNon-Executive Director€31,770
- Mr. Jean-francois HenauxNon-Executive Director - Employees Representative€88,994
- Mrs. Virginie HeurtautNon-Executive Director€31,770
- Mr. Sylvain MossazNon-Executive Director - Employees Representative€95,712
- Mr. Gregory WalterNon-Executive Director - Representative of Shareholder Employees€62,883
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 70
- Environment
- 99
- Social
- 95
- Governance
- 17
- Women in the workforce
- 67.9%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Brand: Boiron SA is a well-known and respected brand in the pharmaceutical industry.
- Strong Research & Development: The company invests heavily in R&D, resulting in a strong pipeline of innovative products.
- Global Presence: Boiron SA has a presence in multiple countries, allowing for diversification and access to different markets.
Weaknesses
- Limited Product Range: Boiron SA primarily focuses on homeopathic medicines, which may limit market potential.
- Dependence on Regulatory Environment: Changes in regulations or government policies can impact the company's operations and sales.
- Vulnerability to Counterfeit Products: As a popular brand, Boiron SA faces the risk of counterfeit products, which can harm its reputation.
Opportunities
- Growing Demand for Natural Remedies: Increasing consumer interest in natural and holistic healthcare presents an opportunity for Boiron SA to expand its market share.
- Emerging Markets: Boiron SA can explore expansion in emerging markets where there is a growing demand for healthcare products.
- Online Sales Channels: The company can leverage e-commerce platforms to reach a larger customer base and enhance its sales.
Threats
- Intense Competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share.
- Patents and Intellectual Property: Boiron SA's patents and intellectual property rights may be infringed upon by competitors.
- Shifting Consumer Preferences: Changes in consumer preferences or a lack of trust in homeopathic medicines can impact the demand for Boiron SA's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.